An investigation of serum soluble interferon receptor levels in patients with renal cell carcinoma

Japanese Journal of Urology

Volumn 91, Issue 5, 2000, Pages 514-519

  Iseda, Tokuhiro ^a   Yokoyama, Masayoshi ^a   Kanayana, Hiroomi ^b   Oomoto, Yasukazu ^c   Kagawa, Susumu ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tokusima Medical University

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Marker of RCC; Renal cell carcinoma; Serum soluble interferon receptor

Indexed keywords

ALPHA INTERFERON RECEPTOR; INTERFERON RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; KIDNEY CARCINOMA; MEASUREMENT; PROGNOSIS; SURVIVAL RATE;

EID: 0034122598     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.91.514     Document Type: Article

References (19)

1. Ortaldo, J.R., Herberman, R.B., Harvey, C., Osheroff, P., Pan, Y., Kelder, B. and Pestka, S. : A species of human α Interferon that lacks the ability to boost human natural killer activity. Proc. Natl. Acad. Sci. USA, 81, 4926-4929, 1984.
2. Greiner, J.W., Fisher, P.B., Pestka, S. and Schlom, J. : Differential Effects of Recombinant Human Leukocyte Interferons on Cell Surface Antigen Expression. Cancer Research, 46, 4984-4990, 1986.
3. Uze, G., Lutfalla, G. and Gresser, I. : Genetic transfer of a functional human interferon α receptor into mouse cells : cloning and expression of its cDNA. Cell, 60, 225-234, 1990.
4. Schmidt, A., Zilberstein, A., Schulman, L., Pederman, P., Berissi, H. and Revel, M. : Interferon Action : Isolation of nuclease, a translation inhibitor activated by interferon-induced (2′ 5′ ) oligoisoadenylate. FEBS. Lett., 95, 275-279, 1978.
5. Horoszewicz, J.S. and Murphy, G.P. : An assessement of the current use of human interferons in therapy of urologic cancers. J. Urol., 142, 1173-1180, 1989.
6. Vogelzang, N.J., Lipton, A. and Figlin, R.A. : Subcutaneous interleukin-2 plus interferon Alfa-2a in metastatic renal cancer : an outpatient multicenter trial. J.Clin. Oncol., 11, 1809-1816, 1993.
7. Foon, K., Doroshow, J., Bonnem, E., Fefer, A., Graham, S., Grosh, B., Narayan, P., Elias, L., Harvey, H., Schulof, R., Williams, R., Rinehart, J., Zekan, P., Catalona. W., Dillman, R., Salmon, S. and Galasso, F. : A prospective randomized trial of alpha 2B-interferon gamma interferon or the combination in advanced metastatic renal cell carcinoma. J. Biol. Response Mod., 7, 540-545, 1998.
8. Schornagel, J.H., Verweij, J., Bokkel Huinink, W. W, Klijn, J.G. M., Mulder, P.H. M., Debruyne, F.M. J., Deijk, W.A., Roozendaal. K., Kok, T.C., Veenhof, K.H. N., Berkel, J. and Oosterom, A.T. : Phese II study of recombinant interferon alpha-2A and vinblastine in advanced metastatic renal cell carcinoma. J.Urol., 142, 253-256, 1989.
9. Kinouchi, T., Saiki, S., Maeda, O., Kuroda, M., Usami, M. and Kotake, T. : Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-α and cimetidine. J.Urol., 157, 1604-1607, 1997.
10. Carithers, R.L. Jr. and Emerson, S.S. : Therapy of hepatitis C : meta-analysis of Interferon alfa-2b trials. Hepatology. 26 Suppl., 1, 83S-88S, 1997
11. Mohler, K.M , Sleath, P.R., Fitzner, J.N., Cerretti, D. P., Alderson, M., Kerwar, S.S., Torrance, D.S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., Kronheim, S.R., Petersen, M., Gerhart, M., Kozlosky, C.J., March, C.J. and Black, R.A. : Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature, 370, 218-220, 1994.
12. Gearing, A.J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A.H., Drummond, A.H., Galloway, W.A., Gilbert, R., Gordon, J. L., Leber, T.M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M. and Woolley, K. : Processing of tumor necrosis factor-α precursor by metalloproteinases, Nature, 370, 555-557, 1994.
13. McGeehan, G.M., Becherer, J.D., Bast Jr., R.C., Boyer, C.M., Champion, B., Connolly, K.M., Conway, J.G., Furdon, P., Karp, S., Kidao, S., McElroy, A.B., Nichols, J., Pryzwansky, K.M., Schoenen, F., Sekut, L., Truesdale, A., Verghese, M., Warner, J. and Ways, J.P. : Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature, 370, 558-561, 1994.
14. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K. and Scheurich, P. : The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell, 83, 793-802, 1995.
15. Quesada, J.R., Rios, A., Swanson, D., Trown, P. and Gutterman, J.U. : Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol., 3, 1522-1528, 1985.
16. Prummer, O. : interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2a in an adjuvant multicenter trial. Cancer, 71, 1828-1834, 1993.